Результаты поиска

Neutrophil-to-lymphocyte ratio correlates with prognosis and response to chemotherapy in patients with non-M3 de novo acute myeloid leukemia.

BackgroundNeutrophil-to-lymphocyte (NLR) ratio can predict survival outcome and assess response to chemotherapy in several tumors. However, the values of NLR in acute myeloid leukemia (AML) remains unknown.MethodsA retrospective review of 181 patients with de novo AML excluding acute promyelocytic leukemia (M3) was conducted in our institute. We categorized the patients into two groups by defining NLR =2.0 as the cut-off point. NLR was calculated by the ratio of the number of neutrophils to lymphocytes in the peripheral blood (PB). The baseline clinicopathologic parameters were compared using

Совпадение в полном тексте источника
… Cytogenetic analysis The vast majority of patients had cytogenetic analysis at the initial time of diagnosis by R- and/or G-banding techniques and classification according to the International System for Human Cytogenetic Nomenclature. … Secondly, a portion of patients only completed BM morphologic and immunologic and cytogenetic analysis, but no molecular biologic analysis due to high medical costs. …

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH).

This round table discussion organized by the International Academy for Clinical Hematology (IACH) was dedicated to the 19th annual meeting of the International Myeloma Society (IMS), which was held in Los Angeles between the 25th and 27th August 2022. After some key meetings of the discipline of the field of clinical hematology, the IACH organizes regular round table discussion in order to summarize the flow of information and get the opinion of a panel of experts and the key take-home messages. As part of this discussion, the panellists debated 6 key topics: disease monitoring, management of

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

In the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1-3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone (Vd). Compared with Vd, XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy, with trends in overall survival (OS) favoring XVd. In BOSTON, 141 (35.1%) patients had MM with high-risk (presence of del[17p], t[4;14], t[14;16], or ≥4 copies of a

Прогнозирующее значение динамического мониторинга состояния минимальных остаточных заболеваний у пациентов с множественной миеломой: исследование реального мира.

Фон: Минимальное остаточное заболевание (МВД) является установленным прогнозным фактором в миеломе (ММ), однако значение динамических изменений MRD до и после аутологической трансплантации стволовых клеток (ASCT) остается неясным. Методы: Ретроспективный анализ 335 Недавно диагностировали пациентов MM, прошедших первичную ACCT. Общий показатель выживаемости (ОС) и выживаемости без прогрессирования (ПФС) оценивался с использованием метода Kapan-Meier и сопоставлялся с использованием теста log-rk. Для оценки коэффициентов опасности (HR) и 95% Интервал доверия (CI), коррекция с учетом клинических

Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview.

Karyotype is one of the main constituents of the International Prognostic Scoring System (IPSS) and revised-IPSS that are the cornerstones for the prognostication of patients with myelodysplastic syndromes (MDS). Del(5q), -7/del(7q), +8 and -Y are among the most extensively studied cytogenetic abnormalities in MDS. The same applies for normal karyotype. There are hundreds of other rare cytogenetic abnormalities that have been reported in MDS, included but not limited to -X, 3q abnormalities, +13/del(13q), i(17q), +21/-21. However, due to a very low number of patients, their impact on the progn

Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.

Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia (BCP-ALL) carries an immunoglobulin- MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukemia and use of individualized treatment schedules of unproven efficacy. Here we compare the molecular characteristics of these conditions and investigate historic clinical outcome data. We identified 90 cases registered in a national BCP-ALL clinical trial/registry. When present, diagnostic material underwent cytogenetic, exome, methylome and transcriptome analyses. The outcomes

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients.

Objective Myeloma-related bone disease (MBD) is one of the most common complications of multiple myeloma (MM). This study aims to investigate the correlation between serum bone metabolism indexes (BMIs), the clinical characteristics and prognosis of newly diagnosed MM (NDMM) patients.MethodsThe serum BMIs of 148 patients with NDMM in a single hematological disease treatment center from April 2014 to December 2019 were analyzed retrospectively, including type I collagen amino terminal elongation peptide (PINP), β-C-terminal telopeptide of type I collagen (β-CTX) and N-terminal osteocalcin (N-MI

Характеристики пожилых корейских пациентов в возрасте нескольких миэлома 80 годами или более.

Множественная миелома (ММ) затрагивает главным образом пожилых людей, однако исследования, касающиеся пожилых пациентов с ММ, ограничены. Клинические характеристики и результаты выживаемости пациентов с возрастом MM 80 В ходе ретроспективного анализа были проанализированы годы или более. МЕТОДЫ: Это ретроспективное многоцентральное исследование было проведено для изучения клинических характеристик, методов лечения и результатов выживаемости пациентов пожилого возраста. 80 и старше, которым был поставлен новый диагноз five - академические больницы в Тэгу, Корея, между 2010 и 2019.РЕЗУЛЬТАТЫ: Вс

A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.

Real-world studies permit inclusion of a more diverse patient population and provide more information on the effectiveness of treatments used in routine clinical practice. This prospective, multicenter, observational study investigated the effectiveness and safety of ixazomib plus lenalidomide and dexamethasone (IRd) in 295 patients with relapsed/refractory multiple myeloma (RRMM) in routine clinical practice in Japan. Patients had a median age of 74 years, 80.0% were aged ≥ 65 years, 42.0% had received ≥ 3 lines of prior treatment, and 28.5% were "frail" according to the International Myeloma

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.

Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted to patients up to 65 years of age. Prospective phase III trial data in the era of novel agents for patients up to 70 years of age are not available. The GMMG-MM5 trial included 601 patients between 18 and 70 years of age, divided in three groups for the present analysis: ≤60 years (S1, n = 353), 61-65 years (S2, n = 107) and 66-70 years (S3, n = 1

Abstracts of the 12th European Cytogenomics Conference 2019 : Salzburg, Austria. 6-9 July 2019

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.

BackgroundWe have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice.MethodsA total of 344 patients treated with IRD (N = 127) or RD (N = 217) were selected for analysis from the Czech Registry of Monoclonal Gammopathies (RMG). Descriptive statistics were used to assess patient's characteristics associated with the respective therapy. The primary endpoint was progression free survival (PFS

Case report: CD8 positive T-cell Prolymphocytic Leukemia presenting complex karyotype with a rare chromosomal abnormality der(2)t(1;2)(q21;q37) and additional signals of the genes MYC, IGH, and TP53.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… The cytogenetics analysis also showed a deletion in 11q, confirmed by the interphase FISH with the probe for the ATM gene. … In this case, the cytogenetic analysis uncovered a complex karyotype (CK), including the dual translocation of chromosome 14, rearrangements on chromosomes 9p and 5p, isochromosome 8, deletion 11q, and monosomy 17. …

Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse after Autologous Stem Cell Transplantation.

Clinical relapses early after autologous stem cell transplantation portrays an inferior clinical outcome. Early relapse in this setting with extramedullary disease (EMD) of lung involvement in multiple myeloma is rare. To our knowledge, this is the first reported case of lymphangitic spread of myeloma with pulmonary parenchymal and pleural involvement occurring at first relapse.

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Continuous lenalidomide-dexamethasone (Rd)-based regimens are among the standards of care in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. The oral proteasome inhibitor ixazomib is suitable for continuous dosing, with predictable, manageable toxicities. In the double-blind, placebo-controlled TOURMALINE-MM2 trial, transplant-ineligible NDMM patients were randomized to ixazomib 4 mg (n = 351) or placebo (n = 354) plus Rd. After 18 cycles, dexamethasone was discontinued and treatment was continued using reduced-dose ixazomib (3 mg) and lenalidomide (10 mg) until progres

Реагирующие кинетики как динамический прогнозный маркер у пациентов с множественной миеломой.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre-BCMA Era: A Prospective, Single-Centre Study.

OBJECTIVES: Minimal/measurable residual disease (MRD) negativity in multiple myeloma (MM) is associated with favourable outcomes; nonetheless, evidence supporting treatment discontinuation remains limited. We evaluated the feasibility of discontinuing antimyeloma therapy in patients with MRD negativity. METHODS: We analysed 41 patients who discontinued therapy after achieving MRD negativity at the 10-5 level in the bone marrow (BM) and on imaging studies. Treatment regimens and lines of therapy were not prespecified. After discontinuation, patients were monitored with periodic MRD assessments

Анализ Four Пациенты отключают Idecabtagen Vicleucel после Leukapheres из-за Multieloma Progression.

В настоящем докладе four - пациенты, которые не смогли получить idecabtagen vicleucel (ide-cel) из-за развития болезни, несмотря на то, что они проходили лейкаферез в соответствии с техническими требованиями. Средний возраст пациентов составлял 70 (дальность, 68-77) лет. Two у пациентов были не секретарские подтипы на диагнозе. Среднее число предыдущих терапевтических линий составило 4.5 (дальность, 4-6) и 3 Пациенты были пента-реакторами. Все пациенты отказались от последнего лечения. Среднее время от аферы до отмены ide-cel 44.5 (ассортимент: 24-71) дней. Наши выводы свидетельствуют о том, ч

Совпадение в полном тексте источника
… A cytogenetic analysis revealed cyclin D1 (CCND1)-IgH translocation t(11;14) by fluorescence in situ hybridization (FISH) analysis, and complex karyotype abnormalities were detected by a G-band analysis. … A reevaluation of the cytogenetic analysis of MM cells showed a complex karyotype with 1q21 amplification ( Fig. 2 ). …

Clinical Characteristics, Cytogenetic Risks, and Prognoses of Young Multiple Myeloma Patients in the Era of Novel Therapies.

Background/Objectives: In recent years, there have been significant advances in the understanding and treatment of multiple myeloma (MM). Despite this progress, there is still limited information on the disease in patients aged 50 or younger, including the impact of young age on disease characteristics, treatment, and outcome. Methods: In this retrospective study, we analyzed 68 newly diagnosed MM patients aged ≤ 50 years (y) who had undergone at least one peripheral blood stem cell transplantation (PBSCT). Additionally, we reviewed data published during 2008-2022 and compared these to our coh

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.

Immunoglobulin D (IgD) myeloma is a subtype often considered to have adverse features and inferior survival, but there is a paucity of data from large clinical studies. We compare the clinical characteristics and outcomes of patients with IgD myeloma from UK phase 3 myeloma trials analyzed in 2 groups: old (1980-2002) and recent (2002-2016) clinical trials, based on the time of adoption of novel myeloma therapies. Patients with IgD myeloma comprised 44 of 2789 (1.6%) and 70 of 5773 (1.2%) of the old and recent trials, respectively. Overall, IgD myeloma was associated with male predominance, lo